Medical artificial intelligence (AI) company Runit (CEO Seo Beom-seok) announced on the 27th that it held its 12th regular shareholders' meeting at the Camco Yangjae Tower in Gangnam-gu, Seoul on the 27th and passed a total of 7 agenda items as originally proposed.
At the general shareholders' meeting on that day, all major agenda items were passed, including ▲new appointment of SBVA CEO Lee Jun-pyo as an outside director and auditor, ▲reappointment of outside director Garheng Kong, ▲approval of the 12th financial statements, and ▲approval of the director compensation limit.
At the general meeting of shareholders, Runit appointed Lee Jun-pyo, CEO of SBVA, as an outside director to provide new momentum to its global growth strategy. With expertise in AI and information and communication technology (ICT), this outside director has built a successful investment portfolio of global AI companies, and based on this experience, he is expected to play a key role in Runit’s technological innovation and global market expansion.
In addition, Runit has reappointed Garheng Kong, founder of HealthQuest Capital, who has served as an outside director since 2022. Kong has played a key role in building Runit’s global business network and will continue to contribute to establishing global sales strategies in the future.
In particular, at this general shareholders meeting, Runit reexamined its financial strategy to reflect the challenges of the rapidly changing global economic environment and presented a specific roadmap to achieve successful business performance.
Ken Nesmith, Chief Business Officer (CBO) of Lunit SCOPE, explained in the announcement that in addition to the partnership with AstraZeneca officially announced last year, Lunit SCOPE is currently discussing new partnerships with a number of global big pharma companies based on its technological differentiation.
Seo Beom-seok, CEO of Lunit, said, “Outside Director Lee Jun-pyo’s global investment capabilities and in-depth insight into the AI industry as a whole will serve as a solid foundation for Lunit’s current global market entry strategy.” He added, “We will lead the global medical AI industry through balanced growth of ‘Lunit Insight,’ which is continuing stable sales growth, and ‘Lunit Scope,’ which is about to collaborate with a global big pharma.”
- See more related articles
You must be logged in to post a comment.